LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation

Muchaala Yeboah, … , Mark S. Cragg, Ali Roghanian

JCI Insight. 2020;5(18):e141593. https://doi.org/10.1172/jci.insight.141593.

Graphical abstract

Find the latest version:
https://jci.me/141593/pdf
LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation

Muchaala Yeboah,1 Charys Papagregoriou,1 Des C. Jones,1 H.T. Claude Chan,1 Guangan Hu,3 Justine S. McPartlan,1 Torbjörn Schiött,4 Ulla-Carin Tornberg,4 Björn Hambe,6 Anne Ljungars,4 Mikael Mattsson,4 Ivo Tews,5,6 Martin J. Glennie,1 Stephen M. Thirdborough,1 John Trowsdale,2 Björn Frendeus,4 Jianzhu Chen,3 Mark S. Cragg,1 and Ali Roghanian1,3

1Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom. 2Division of Immunology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom. 3Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. 4BioInvent International AB, Lund, Sweden. 5Institute for Life Sciences and 6Biological Sciences, University of Southampton, Southampton, United Kingdom.

Introduction

Molecules of the human leukocyte immunoglobulin-like receptor (LILR) family, discovered over 2 decades ago (1, 2), are expressed on leukocytes and are commonly dysregulated in a wide range of pathologies (3–5). There are 5 activating (LILRA1, 2, 4–6), 5 inhibitory (LILRB1–5), and 1 soluble (LIL-RA3) LILR that together regulate immune responses (3). They display 2, or 4, homologous C-2–type Ig-like extracellular domains but differ in their transmembrane and cytoplasmic regions (2, 6). LILRA have short truncated cytoplasmic tails with charged arginine residues in their transmembrane domains, facilitating association with the immunoreceptor tyrosine-based activation motif–bearing Fcε receptor γ chain to propagate activating signaling cascades (7). Conversely, LILRB have long cytoplasmic tails that contain multiple immunoreceptor tyrosine-based inhibition motifs (ITIMs), which recruit phosphatases such as SHP-1 and SHIP-1 to elicit inhibitory signaling (2, 6). Located at human chromosome 19q13.4, these receptors demonstrate significant allelic variation, with LILRB3, LILRB4 (ILT3), and LILRA6 (ILT8) each displaying at least 15 variants (2, 8–10).

The LILRB molecules are proposed to act as immune checkpoints serving to control and limit overt immune responses (3). In agreement with this, LILRB expression is increased in suppressive (also referred to as alternatively activated or M2) macrophages and tolerogenic dendritic cells (DCs) (11–15). On monocytes, coligation of LILRB1 (ILT2) and LILRB2 (ILT4) with the activatory Fcγ receptor I (CD64) results in SHP-1 activation, decreasing downstream phosphorylation events and intracellular calcium mobilization (16). Engagement of LILRB1 on macrophages by the common HLA-I subunit, β2-microglobulin, on malignant cells limits their phagocytic potential (17). Similarly, we and others have shown that ligation of LILRB1, 2, or 4 renders DCs tolerogenic, leading to inhibition of T cell responses (11, 12, 15, 18–21).

Despite advances in identifying the key immunoregulatory roles of many of the human leukocyte immunoglobulin-like receptor (LILR) family members, the function of the inhibitory molecule LILRB3 (ILT5, CD85a, LIR3) remains unclear. Studies indicate a predominant myeloid expression; however, high homology within the LILR family and a relative paucity of reagents have hindered progress toward identifying the function of this receptor. To investigate its function and potential immunomodulatory capacity, a panel of LILRB3-specific monoclonal antibodies (mAbs) was generated. LILRB3-specific mAbs bound to discrete epitopes in Ig-like domain 2 or 4. LILRB3 ligation on primary human monocytes by an agonistic mAb resulted in phenotypic and functional changes, leading to potent inhibition of immune responses in vitro, including significant reduction in T cell proliferation. Importantly, agonizing LILRB3 in humanized mice induced tolerance and permitted efficient engraftment of allogeneic cells. Our findings reveal powerful immunosuppressive functions of LILRB3 and identify it as an important myeloid checkpoint receptor.
As such, the engagement of LILRB1 and LILRB2 by their high-affinity ligand HLA-G is an important immunosuppressive pathway at the fetal-maternal interface during pregnancy (22–24) and may be involved in tumor immunoevasion (5).

Although mice do not express LILRs, they possess an orthologous system composed of 2 paired Ig-like receptors (PIRs): the activating PIR-A and the inhibitory PIR-B. PIR-B regulates priming of cytotoxic T lymphocytes by DCs through interaction with MHC class I (MHC-I) (25) and negatively influences integrin signaling in neutrophils and macrophages (26). Furthermore, PIR-B regulates the differentiation of myeloid-derived suppressor cells (MDSCs) that aid tumor progression (27).

Among the inhibitory LILRB molecules, LILRB3 (ILT5/LIR3/CD85a), containing 4 extracellular Ig-like domains and 4 cytoplasmic ITIMs, represents an attractive immunomodulatory target because of its relative restriction to, and high expression on, myeloid cells (3, 4). However, due to the lack of specific reagents and model systems, its exact functions and immunoregulatory potential have not been fully explored. In this study, we addressed this by generating a bespoke panel of novel LILRB3-specific mAbs, some of which were used to probe the function of LILRB3 in relevant preclinical platforms. Our data demonstrate that LILRB3 activation confers potent immunoinhibitory functions through reprogramming and tolerizing of myeloid cells and suggest that modulating LILRB3 activity may provide exciting new treatment strategies in various disease settings, such as transplantation.

Results

Generation and characterization of a panel of fully human LILRB3-specific mAbs. To study the protein expression and function of LILRB3, LILRB3-specific antibodies were identified from a human antibody phage-display library, n-CoDeR (28, 29). Initial alignment analysis of extracellular domains of LILRB1–5 indicated the presence of a limited number of conserved amino acid (a.a.) residues across the LILRB3 ectodomain (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.141593DS1), against which specific mAbs could be generated. In this regard, phages binding to the “target” ectodomain of LILRB3 protein (present in solution, coated on a plastic surface, or expressed on cells), and not to the homologous (~65% extracellular homology) “nontarget” LILRB1 ectodomain protein, were selected (Figure 1A and Supplemental Figure 2). To increase specificity and yield, the cross-reactive phages were initially removed through a preselection (negative selection/depletion using “nontarget” proteins), followed by the selection itself (positive selection). Following each selection round, the selected clones were screened against the ectodomains of both LILRB1 and LILRB2 by fluorometric microvolume assay technology (FMAT) and ELISA, and cross-reactive clones were further excluded from the panel. After 3 rounds of phage panning and enrichment, successful selection of clones specific for LILRB3 was reconfirmed by FMAT and ELISA, with target-specific phages converted to soluble single-chain variable fragment (scFv) and screened further (Figure 1, B and C). Successful clones were selected based on binding to LILRB3 and lack of cross-reactivity to LILRB1 and LILRB2. Selected scFv clones (>200) were then sequenced and tested for binding against primary cells and LILRB transfectants using high-throughput flow cytometry (Figure 1D).

Subsequently, 46 candidate target-specific clones were converted to human IgG1 (hIgG1) and, in addition to screening against LILRB1–3 transfectants, to exclude those with potential broader LILR cross-reactivity, were screened against a larger panel of LILR-expressing cell lines (Figure 1E). Due to cross-reactivity to one or more other LILR family members, as exemplified by clone A30 (Figure 1E, bottom panel), 30 mAb clones were further excluded at this stage. In total a panel of 16 LILRB3-specific antibodies were identified for further study. These LILRB3-specific clones were further tested and confirmed to have no cross-reactivity to the mouse orthologue, PIR-B (data not shown). A selection of these mAbs were then fluorochrome labeled and used to determine the LILRB3 expression profile on human peripheral blood leukocytes, demonstrating predominant staining of monocytes and to a lesser extent granulocytes (Figure 1, F and G), in agreement with previous reports (2, 3, 6). The immunophenotyping also revealed that LILRB3 expression was significantly higher on circulatory CD14hiCD16– classical and CD14+CD16lo intermediate monocytes compared with the more inflammatory CD14+CD16hi nonclassical monocytes (Figure 1, F and G).

The selected LILRB3 mAbs were also tested for their specific binding properties. Surface plasmon resonance (SPR) analysis showed that all LILRB3-specific clones bound to recombinant LILRB3-hFc protein in a dose-dependent manner (as represented by A16; Figure 2A) and displayed a range of affinities (Table 1). Interestingly, all mAbs had similar association rates (~10^9) but varied in their dissociation rates by 3 orders of magnitude (~10^-3 to 10^-6).
LILRB3 ligation modulates T cell activation and proliferation. Accordingly, using a select number of mAbs, we sought to investigate the immunomodulating effect of the LILRB3 mAbs on cellular effector functions. LILRB1 has previously been shown to directly inhibit T cell responses by causing dephosphorylation of the CD3 signaling cascade, and, in addition, has the potential to negatively regulate T cell activation by competing with CD8 for HLA-I binding (31, 32). Moreover, LILRBs can indirectly inhibit T cell responses by rendering antigen-presenting cells (APCs), such as monocytes and DCs, tolerogenic (14, 18, 33). To investigate the immunomodulatory potential of LILRB3 and its ability to regulate adaptive immune responses, we used a T cell proliferation assay incorporating fresh PBMCs isolated from healthy human donors, as before (34). Fcγ receptors (FcγRs) help mediate the effects of IgG (35). Therefore, to study the direct F(ab′):LILRB3-mediated effects of the mAb on T cell proliferation, they were first deglycosylated to reduce FcγR-IgG interactions. SDS-PAGE showed a decrease in molecular weight of deglycosylated mAbs compared with WT controls, indicative of successful deglycosylation (Figure 3A). The mAbs were then introduced to a T cell proliferation assay where CD3 and CD28 antibodies elicited cell clustering and CFSE dilution, indicative of a significant increase in CD8+ T cell proliferation, compared with nontreated controls (Figure 3, B and C). Clone A1, shown to be an agonist (Figure 2D), significantly inhibited CD8+ T cell proliferation in this assay when compared with the isotype control (Figure 3, B and C). Similarly, the commercial antibody (clone 222821) substantially inhibited T cell proliferation (data not shown). Other LILRB3-specific mAbs had either no or subtle effects, as represented by clones A16 and A28. These data demonstrate that LILRB3 ligation by agonistic mAbs suppresses T cell responses, whereas other clones...
Figure 2. Characterization of LILRB3 antibodies. (A) LILRB3 mAb affinity assessed by SPR. LILRB3-hFc recombinant protein was immobilized, and various LILRB3 mAbs flowed across the chip. Representative LILRB3 clone A16 shown. (B) LILRB3 domain epitope mapping. HEK293F cells transfected with WT LILRB3 (full-length extracellular portion), D1–3, D1–2, or D1 were stained with LILRB3 clones, followed by an anti-hIgG secondary antibody. Schematic of domain constructs and restriction digest of each DNA construct shown (top panel). Histograms showing staining of 2 representative clones differentially binding to color-coded cells expressing WT (D4), D1–3, D1–2, and D1 (bottom panel; n = 3 independent experiments). (C) Ability of generated mAbs to cross-block binding of a commercial LILRB3 mAb (clone 222821). PBMCs were stained with unconjugated LILRB3 antibody clones and subsequently stained with a directly conjugated 222821 mAb and analyzed by flow cytometry; representative clones displayed (A1 nonblocking; A12 partial blocking), as indicated. (D) LILRB3 2B4 reporter cells were incubated with 10 μg/mL LILRB3 antibodies overnight to assess receptor signaling potential as judged by GFP induction measured by flow cytometry; representative clones with percentage of GFP expression shown (n = 2 independent experiments).
LILRB3 ligation induces immune tolerance in humanized mice. Given these data showing that T cells could be suppressed following LILRB3 ligation on myeloid cells, we next investigated the possible effects of LILRB3 modulation in an allogeneic engraftment model using humanized mice, previously reconstituted with primary human fetal hematopoietic stem/progenitor cells (HSPCs) (Figure 4A). Characterization of peripheral blood leukocytes and bone marrow of adult humanized mice demonstrated that LILRB3 was expressed on, and restricted to, myeloid cells, but not lymphocytes, similar to humans (Figure 4B and Supplemental Figure 4). We recently showed that allogeneic human lymphoma cells are readily rejected in humanized mice due to HLA mismatch (36). To test the potential of LILRB3 ligation to suppress the allogeneic immune response, adult humanized mice were treated with the agonistic LILRB3 mAb (A1) and the engraftment of allogeneic human B cell lymphoma cells, derived from an unrelated donor (36, 37), was monitored over time (Figure 4A). LILRB3 mAb treatment was able to induce a state of tolerance in vivo and led to a successful engraftment of the donor allogeneic cells (Figure 4C). Accordingly, LILRB3-treated tumor-bearing humanized mice subsequently succumbed to disease with high tumor burden, whereas isotype control–treated mice readily rejected the lymphoma cells without morbidity (Figure 4D). These observations corroborate our in vitro functional assays and identify LILRB3 as a key regulator of immune tolerance in an allotransplant setting. Given the expression pattern of LILRB3 on myeloid but not lymphocytic cells in both the human PBMCs and humanized mice, we sought to explore the effects of the LILRB3 mAbs on these cells.

LILRB3 ligation leads to transcriptional modification and M2 skewing of human APCs. To investigate the pathways and factors involved in LILRB3-mediated immunosuppression, we next investigated the transcriptomic changes in monocytes following LILRB3 engagement. Short-term (~18-hour) in vitro treatment of freshly isolated human peripheral CD14+ monocytes with the agonistic LILRB3 mAb (A1) caused a dramatic shift in their phenotype (Figure 5A), with the cells displaying a significantly more elongated morphology ($P < 0.0001$)

| Table 1. LILRB3 mAb characterization |
|--------------------------------------|
| **Clone ID** | **Ig-like domain** | **Blocking potential** | **Affinity ($K_d$)** |
| 1 (A1) | 4 | N | $3.12 \times 10^{-10}$ |
| 2 (A12) | 2 | Y | $5.30 \times 10^{-10}$ |
| 3 | 4 | N | $2.92 \times 10^{-10}$ |
| 4 (A16) | 4 | N | $2.88 \times 10^{-9}$ |
| 5 | 2 | Y | $1.04 \times 10^{-9}$ |
| 6 | 2 | N | $1.55 \times 10^{-9}$ |
| 7 | 4 | N | $3.85 \times 10^{-10}$ |
| 8 (A28) | 4 | N | $1.45 \times 10^{-9}$ |
| 9 | 4 | N | $9.84 \times 10^{-9}$ |
| 10 | 2 | N | $3.71 \times 10^{-10}$ |
| 11 | 4 | N | $1.37 \times 10^{-9}$ |
| 12 | 4 | N | $1.24 \times 10^{-10}$ |
| 13 | 4 | N | $3.25 \times 10^{-9}$ |
| 14 | 2 | N | $3.05 \times 10^{-10}$ |
| 15 | 4 | N | $1.56 \times 10^{-9}$ |
| 16 | 2 | N | $1.68 \times 10^{-8}$ |
| 222821 | 2 | - | $1.47 \times 10^{-11}$ |

Summary of binding domain, blocking potential, and affinity measurements for the selected LILRB3–specific mAbs. Clone 222821 represents the commercial LILRB3 mAb (mIgG2a). Ability to block binding of clone 222821 is indicated by yes (Y) or no (N). Affinity assessed using the univalent model of 1:1 binding by SPR; clone IDs described herein are indicated in parentheses.
resembling immunosuppressed M2 macrophages (38). In accordance with this, RNA-Seq analysis revealed that ligation of LILRB3 on monocytes induced a signature resembling “M2-skewed” immunosuppressive macrophages (Figure 5B). Concurrently, the expression of genes associated with “M1-skewed” immunostimulatory macrophages was downregulated in LILRB3-ligated monocytes (Figure 5, B and C). These data were confirmed by quantitative PCR (qPCR) for a number of the differentially regulated genes on a further 6 donors (Figure 5D). As further evidence, we showed that the effects were dependent upon LILRB3 agonism because treatment of monocytes with a nonagonistic LILRB3 mAb (A28), despite binding the same domain, did not affect monocyte phenotype or gene expression (Figure 5D). Gene set enrichment analysis (GSEA) of the RNA-Seq data showed a positive correlation with gene signatures reported for suppressive macrophages, e.g., oxidative phosphorylation (39). Conversely, LILRB3-ligated monocyte gene signatures negatively correlated with those reported for inflammatory macrophages, e.g., IFN-γ and IFN-α responsive elements, as well as allograft rejection (Figure 5E), in line with our in vivo observations (Figure 4). In summary, these
data show that LILRB3 activation results in significant phenotypic and transcriptional alterations in human primary myeloid cells, leading to potent inhibition of downstream immune responses.

**Discussion**

We previously demonstrated that ligation of LILRB1 on human DCs induces a tolerogenic phenotype, hindering T cell responses (18, 40). In this study, we investigated another inhibitory LILR family member, LILRB3, whose function, largely due to lack of suitable reagents and experimental systems, is not yet fully determined. Limited previous studies investigated the consequences of LILRB3 ligation on granulocytes and have demonstrated its inhibitory function on neutrophils (41) and basophils (42) in culture. Here, we largely concentrated on myelomonocytic cells and the subsequent regulation of adaptive immune responses. We, therefore, initially generated and characterized an extensive panel of fully human mAbs with specificity for LILRB3 through a number of stringent panning and selection processes.
Human LILRB3 ligation reprograms human primary myeloid cells. Freshly isolated human peripheral CD14+ monocytes were treated with an isotype control (iso ctrl) or a human LILRB3 mAb (clone A1) and then assessed. (A) Agonistic LILRB3 mAb (clone A1) affects monocyte morphology. Light microscopy images following overnight treatment of freshly isolated CD14+ monocytes with indicated mAbs in culture (original magnification, ×10; left panel). Images of treated monocytes were analyzed and length of monocytes quantified (right panel). A total of 200–500 individual cells were analyzed per image. Combined data from 3 independent donors shown; lines indicate median; 2-tailed paired t test performed (**P < 0.0001). (B) Transcriptional analysis of LILRB3-treated monocytes reveals upregulation of M2-associated genes compared with controls. RNA was extracted from cells following mAb treatment (~18 hours) and subjected to RNA-Seq. Red depicts genes that were significantly upregulated, and green depicts genes that were significantly downregulated compared with isotype control–treated cells (n = 5–6 independent donors). (C) Ligation of LILRB3 on primary human CD14+ monocytes downregulated M1-associated genes. GSEA graph showing a significant enrichment for M1-polarizing genes in LILRB3–treated monocytes versus isotype control, respectively. UP, upregulated, normalized enrichment score (NES) = –1.68; family-wise error rate (FWER); P < 0.001. (D) qPCR analysis of selected genes following LILRB3 ligation on monocytes using an agonistic LILRB3 mAb (A1), a nonagonistic LILRB3 mAb (A28), or an isotype control (iso ctrl). Data were normalized to GAPDH mRNA levels and standardized to the levels of isotype control–treated cells (~18 hours) and subjected to RNA-Seq. Red depicts genes that were significantly upregulated, and green depicts genes that were significantly downregulated compared with isotype control–treated cells (n = 5–6 independent donors). Ligation of LILRB3 on primary human CD14+ monocytes downregulated M1–associated genes. GSEA graph showing a significant enrichment for M1-polarizing genes in LILRB3–treated monocytes versus isotype control, respectively. UP, upregulated, normalized enrichment score (NES) = –1.68; family-wise error rate (FWER); P < 0.001. (E) GSEA showing negative correlation with IFN-γ (NES = –2.17; FWER P < 0.001), IFN-α (NES = –2.3; FWER P < 0.001), and allograft rejection (NES = –1.58; FWER P = 0.14) signaling elements and positive correlation with oxidative phosphorylation (NES = 2; FWER P < 0.001).}

Those clones showing cross-reactivity to other human LILR family members were excluded. Immuno-profiling of circulating leukocytes from healthy donors using these highly specific mAbs confirmed the reported expression of LILRB3 on myelomonocytic and granulocytic cells, but not on lymphocytes (2, 3, 6). This pattern of expression on myeloid and granulocytic but not lymphoid cells was confirmed in a large cohort of independent donors (>50), suggesting that, despite the polymorphic nature of LILRB3 (2, 9, 43), the selected antibodies recognize many, if not all, variants, which is important for the development of these reagents for therapeutic applications. Subsequent analysis showed that the LILRB3 mAbs displayed a range of affinities, albeit all within the nanomolar (nM) range, with similar on rates, but off rates differing over 3 orders of magnitude. K_d values in the low nanomolar range are generally considered viable drug candidates; rituximab, for example, has an 8 nM affinity for its target, CD20 (44). This suggests that the LILRB3 mAbs generated here have potential as therapeutic agents. However, because LILRB3 shares high sequence homology (>95%) in its extracellular domain with LILRA6, there is a possibility that our LILRB3 mAbs may also recognize shared epitopes on LILRA6, if coexpressed (9). These initial data might receive further evidence from other reagents as well as investigation as to whether LILRA6 protein is detectable in leukocyte subsets, e.g., using proteomics approaches similar to a recent study with neutrophils (41). Epitope-mapping experiments revealed that the specific LILRB3 mAbs reported herein were generated against 2 specific ectodomains, either Ig-like domain 2 or 4. Interestingly, none of the generated specific LILRB3 mAbs bound to Ig-like domain 1 or 3, suggesting that these domains may not contain epitopes that are unique for LILRB3, or more likely those unique residues are not exposed/accessible. Collectively, these data confirm that our LILRB3 mAbs will be useful tools for dissecting LILRB3’s molecular mechanisms and may additionally have therapeutic benefits in relevant pathologies.

The ability of the LILRB3 mAbs to influence T cell responses was variable, with some inhibiting proliferation, while others resulted in modest increases in proliferation, supportive of agonistic or blocking properties, respectively. Similar to LILRB1 (17, 18, 21), these effects are likely through manipulations of APCs, specifically monocytes, because they are the only cells expressing LILRB3 in the culture. In support of this, the agonistic LILRB3 mAbs did not suppress T cell proliferation in the absence of monocytes. Binding epitopes influence the ability of mAbs to modulate receptor function in many systems (35, 45), and so it was unsurprising to see LILRB3 mAbs capable of differing functions. However, the D4-binding A1 mAb was a strong inhibitor of proliferation, whereas other D4-binding mAbs (e.g., A28) had no significant effect. Therefore, domain-specific epitopes did not seem to correlate directly with LILRB3 mAb–mediated effector cell functions and may not be predictive of LILRB3 mAb function per se. Further detailed analyses, e.g., surface alanine scanning mutagenesis (45) and/or structural studies, are required to define the specific extracellular epitopes engaged by the selected LILRB3 mAbs and to investigate their influence on receptor activity.

Our observations demonstrating immunoinhibitory activities downstream of LILRB3 were further confirmed in the reconstituted humanized mouse model. In this system, where LILRB3 is present only on the hematopoietic cells, and predominantly monocytes, in the absence of appreciable numbers of neutrophils, ligation of LILRB3 with an agonistic LILRB3 mAb before injection of allogeneic lymphoma cells (36, 37) induced tolerance in vivo and enabled subsequent tumor cell engraftment. This demonstrates the
capacity of LILRB3 to exert profound immunosuppressive effects that may be exploited in therapeutic settings, such as autoimmunity and transplantation, where transient induction of immune tolerance will be beneficial. Similar observations were previously reported using a LILRB1 transgenic mouse model, where interactions between LILRB1 and MHCI or HLA-G expanded MDSCs and prolonged allogenic graft survival in vivo (46, 47).

Although typically regarded as an orphan receptor, earlier studies suggest that LILRB3 may associate with cytokeratin-associated proteins such as those exposed on necrotic cancer cells (30). Others have also identified angiopoietin-like protein 5 and bacteria, such as *Staphylococcus aureus*, as a source of potential ligands (48, 49). Therefore, our data provide a strong mechanism of action whereby such endogenous or pathogenic ligands may be able to subvert immune responses by ligating LILRB3 during an ongoing immune response.

To investigate the pathways and factors involved in LILRB3-mediated immunosuppression, we investigated the transcriptomic changes in isolated peripheral myeloid cells following LILRB3 ligation. Over 100 genes were differentially regulated in primary human monocytes following LILRB3 ligation, some of which are known to be associated with M2-polarized macrophages (13, 50). Amphiregulin (*AREG*) was among the genes whose expression was markedly upregulated in LILRB3-ligated monocytes. *AREG* is an epidermal growth factor–like growth factor, responsible for inducing tolerance and immunosuppression, via various mechanisms, including enhancement of Treg activity (51). Furthermore, *AREG* is overexpressed in tumor-associated DCs (52) and suppressive/M2 macrophages (53) and has been suggested to play a crucial role in immunosuppression and cancer progression (54). Similarly a number of other candidates, e.g., *activin A* (55) and *CD276* (56), known for their immunosuppressive functions in myeloid cells were induced upon LILRB3 ligation. Although not formally tested, LILRB3-induced production of soluble factors, such as *AREG*, by myeloid cells may promote the expansion and suppressive capacity of Tregs in the PBMC cultures. Similarly, the reported upregulation of immunoinhibitory receptors, such as CD276 (B7-H3), upon LILRB3 ligation on myeloid cells may restrain the activation of T cells and their proliferative capacity (56, 57). In addition, GSEA demonstrated that ligation of LILRB3 on monocytes substantially affected a number of key pathways and functions. Interestingly, LILRB3-ligated monocytes had a gene signature associated with oxidative phosphorylation, which is the metabolic pathway adapted by M2-polarized myeloid cells and is important for their immunosuppressive activities (39). Such LILRB3-inducible immunosuppressive receptors or soluble factors may be responsible for the suppression observed in our T cell assays and for the induction of tolerance in the humanized mouse model. Our ongoing efforts aim to interrogate these findings further and define the mechanisms responsible for LILRB3-mediated suppression of immune responses at molecular and cellular levels, e.g., via siRNA knockdown or neutralization of *AREG* in monocyte cultures and validation of differentially regulated genes in the humanized mouse models. A recent study investigating the mode of action of glatiramer acetate (Copaxone), a peptide-based drug licensed in the late 1990s, used to treat patients with the relapsing-remitting form of multiple sclerosis that ameliorates autoimmunity, identified LILRB2 and LILRB3 as potential ligands (58). On the other hand, blocking human LILRB2 with antagonistic mAbs on human myeloid cells is able to promote their proinflammatory activity and enhance antitumor responses in preclinical models (58); a LILRB2 mAb (MK-4830) recently entered phase I clinical trials (ClinicalTrials.gov NCT03564691) for advanced solid tumors. Furthermore, recent data by Zhang and colleagues suggest that LILRB4 signaling in leukemia cells mediates T cell suppression and supports tumor cell dissemination to distal organs (59). These recent compelling reports further support our findings, demonstrating that ligation of human LILRB3 induces immunosuppression via reprogramming of myeloid cells (i.e., reducing M1-like maturation and promoting suppressive function).

In conclusion, we generated a specific panel of human LILRB3 mAbs, binding to unique residues located within ectodomain 2 or 4, and used the strongest agonistic clone (A1) to reveal LILRB3’s potent immunoregulatory functions on myeloid cells using bespoke preclinical models. Our data demonstrated that LILRB3 engagement on primary human myeloid cells exerts potent immunoinhibitory functions and that LILRB3-specific mAbs are potentially powerful immunomodulatory agents, with broad applications ranging from transplantation to autoimmunity and beyond, where fine-tuning of immune responses through myeloid cell activity is desired.
Methods

Cell culture
Cell lines were grown at 37°C in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum (FCS) (MilliporeSigma), 100 U/mL penicillin-streptomycin, 2 mM glutamine, and 1 mM pyruvate (Thermo Fisher Scientific) in a humidified incubator with 5% CO₂, FreeStyle 293F medium, in 8% CO₂, shaken at 130 rpm, or FreeStyle CHO medium (Thermo Fisher Scientific) with 8 mM glutamine, in 8% CO₂, shaken at 140 rpm.

Antibody generation and production
*Generation of LILRB3 antibodies.* Generation of LILRB3-specific mAbs was performed using the n-CoDeR phage-display library (28). Three consecutive panning rounds were performed, as well as a prepanning step. In the panning, human (h) Fc fusion proteins containing the extracellular domains of LILRB1 and LILRB3 (LILRB-hFc) were used as “nontarget” or “target,” respectively. These proteins were produced in transiently transfected HEK293F cells (ATCC) followed by purification on protein A, as described previously (35). CHO-S cells (ATCC) transiently transfected to express the various LILRB proteins were also used as targets/nontargets in the panning.

In panning 1, BioInvent n-CoDeR scFv were selected using biotinylated in-house–produced recombinant LILRB3-hFc fusion proteins (captured with streptavidin-coated Dynabeads, Thermo Fisher Scientific) with or without competition or LILRB1-hFc coated onto etched polystyrene balls (Polysciences) or plastic immunotubes. Binding phages were eluted by trypsin digestion and amplified on plates using standard procedures (60). The amplified phages from panning 1 were used for panning 2, the process repeated, and the amplified phages from panning 2 used in panning 3. In the third panning round, however, amplified phages from all 3 strategies were combined and selected against LILRB-expressing CHO-S cells, before making the final LILRB3-specific mAb selection.

Next, the LILRB3-positive scFv from the enriched phage repertoires from panning 3 were subcloned to allow soluble scFv expression in *E. coli*. The soluble scFvs expressed by individual clones were tested for binding against LILRB-transfected CHO-S cells using FMAT and recombinant LILRB protein by ELISA. This allowed the identification of clones binding specifically to LILRB3. Clones were then further reduced in a tertiary screen against CHO-S cells expressing LILRB1–3 and primary cells (PBMCs) using a high-throughput flow cytometry screening system, with data analyzed by TIBCO Spotfire software (TIBColorado). Clones showing specific patterns of binding to LILRB3 were sequenced, yielding LILRB3-specific mAbs.

*Production of full-length IgG.* The unique scFv identified above were cloned into a eukaryotic expression system allowing transient expression of full-length IgG in HEK293-EBNA cells. The antibodies were then purified from the culture supernatants using Protein A affinity chromatography as previously described (35).

*Production of deglycosylated IgG.* To allow dissection of Fc- and F(ab′)-dependent effector functions, IgGs were deglycosylated using PNGase F (Promega) with 0.05 U PNGase/μg IgG, at 37°C for at least 15 hours. Deglycosylation was confirmed by reduction in size of the heavy chain on SDS-PAGE.

Production of domain mutant constructs
Using WT LILRB3 cDNA isolated from healthy donor PBMCs, a series of domain-mutant DNA constructs were generated by overlap PCR to express 1, 2, or 3 LILRB3 Ig-like domains (with domains identified based on annotations in UniProt) for comparison to WT LILRB3 (4 domains). The gene constructs were then cloned into pcDNA3.

Cell transfections
HEK293F cells (1 × 10⁷) were transiently transfected with 10 μg of plasmid DNA by lipofection using 233fectin with Opti-Mem 1 Media (Thermo Fisher Scientific).

Preparation of human leukocytes
PBMCs were isolated from leukocyte blood cones (Blood Transfusion Services, Southampton General Hospital) by gradient density centrifugation using lymphoprep (Axis-Shield) and used for subsequent experiments, as before (61).
Flow cytometry

For cell surface staining, human PBMCs, whole blood, or leukocytes from humanized mice were blocked with 10% human AB serum (MilliporeSigma) for 10 minutes on ice and then stained with the relevant APC-labeled LILRB3 mAb or hIgG1 isotype (BioInvent), alongside the following cell surface markers: human CD14-PE (clone 61D3; eBioscience, Thermo Fisher Scientific), CD20-A488 (rituximab; in-house), CD3-PE-Cy7 (clone HIT3a), CD56-APC-Cy7 (clone 5.1H11) or CD15-Pacific Blue (clone HI98), CD15-PE and CD66B-FITC (clone G10F5), CD45-APC-Cy7 (clone 2D1), and mouse CD45.1-PerCP (clone A20) (all BioLegend). Cells were stained for 30 minutes at 4°C and then washed twice, first in 10% red blood cell (RBC) lysis buffer (Serotec) for PBMCs or 1× Erythrolyse RBC Lysing Buffer (Bio-Rad) for whole blood, then with FACS wash (PBS, 1% BSA, 10 mM NaN₃), before acquisition on a FACSCalibur or FACSCanto II (BD Biosciences) and analysis with FlowJo software (BD Biosciences).

For assays to determine if mAbs bound to similar cross-blocking epitopes, 1 × 10⁶ PBMCs were blocked with 2% human AB serum for 10 minutes and stained with 10 μg/mL unconjugated LILRB3 mAbs for 30 minutes at 4°C. The cells were then stained with directly conjugated LILRB3 mAbs (clone 222821; mouse IgG2a; R&D Systems, Bio-Techne) for 20 minutes at 4°C, before washing and acquisition using a FACSCalibur.

For LILRB3 epitope-mapping studies, LILRB3 domain-mutant-transfected HEK293F cells were stained with the relevant LILRB3 mAb for 25 minutes at 4°C, washed twice, stained with an anti–human-PE secondary antibody (109-116-170 Jackson ImmunoResearch) for 20 minutes at 4°C, before washing and acquisition using a FACSCalibur.

For staining of 2B4 reporter cells expressing LILR-A1, -A2, -A5, -B1, -B2, -B3, -B4, or -B5 (or non-transfected controls) (30, 62), cells were stained with 10 μg/mL LILRB mAb and incubated at 37°C with 5% CO₂, overnight. The following day, the cells were washed and stained with a secondary anti-hIgG antibody (Jackson ImmunoResearch) at 4°C, for 45 minutes. The cells were washed and acquisition was performed using a FACScan (BD Biosciences), with data analyzed with FlowJo software.

Surface plasmon resonance

SPR was performed with the Biacore T100 (GE Healthcare) as per the manufacturer’s instructions. LILRB3-hFc recombinant protein (extracellular LILRB3 domain with an hFc tag) was used as the ligand and immobilized by amine coupling onto a series S sensor chip (CM5). Various LILRB3 mAbs were used as analytes and flowed across the chip, and SPR was measured. \( K_D \) values were calculated from the Univalent model of 1:1 binding by \( K_D = \frac{1}{K_s} \), using the Biacore T100 Evaluation Software (GE Healthcare).

T cell proliferation assay

PBMCs (1 × 10⁷ to 2 × 10⁷) were labeled with 2 μM CFSE at room temperature for 10 minutes. An equal volume of FCS was then added to quench labeling for 1 minute, before washing. Cells were subsequently resuspended in serum-free CTL medium (Immunospot) and plated at 1 × 10⁵ cells/well in a 96-well round-bottom plate (Corning). Cells were then stimulated with 0.02 μg/mL CD3 (clone OKT3, in-house), 5 μg/mL CD28 (clone CD28.2; BioLegend), and 10 μg/mL LILRB3 antibodies or a relevant isotype. Plates were then incubated at 37°C for 4 days, after which time cells were stained with 5 μg/mL CD8-APC (clone SK1; BioLegend), harvested and CFSE dilution measured by flow cytometry, as a readout for T cell proliferation.

HSPC isolation and generation of humanized mice

Humanized mice were generated, as described (36). In brief, human fetal livers were obtained from aborted fetuses at 15–23 weeks of gestation, in accordance with the institutional ethical guidelines (Advanced Bioscience Resources, Inc.). All women gave written informed consent for the donation of their fetal tissue for research. Fresh tissue was initially cut into small pieces and digested with collagenase VI (2 mg/mL; Roche) for 30 minutes at 37°C. Single-cell suspensions were prepared by passing the digested tissue through a 100 μm cell strainer (BD Biosciences). HSPCs were purified using a CD34⁺ selection kit (STEMCELL Technologies); the purity of CD34⁺ cells was 90%–99%, as verified by CD34-PE (clone 561, BioLegend) immunophenotyping. Viability was determined through trypan blue exclusion of dead cells. All cells were isolated under sterile conditions and injected into NOD/SCID IL-2Rγ⁻ (NSG) mice. NSG mice were purchased from The Jackson Laboratory and maintained under specific pathogen–free conditions in the animal facilities at Massachusetts Institute of Technology (MIT). To reconstitute mice, newborn pups (less than 2 days old) were irradiated with 100 cGy using a gamma radiation source and
injected intracardially with CD34+ cells (~2 × 10^5 cells/recipient), as reported previously (36). Around 12 weeks later, human leukocyte cell reconstitution of PBMCs was determined by flow cytometry and calculated as follows: % human CD45+ cells/(% human CD45+ cells + % mouse CD45.1+ cells). Mice with at least 40% human CD45+ leukocytes were used in subsequent experiments.

In vivo allograft assay

Fully reconstituted humanized mice were injected with 200 μg LILRB3 mAb (clone A1) or an isotype-matched (hIgG1) control on day 0 and day 4, i.v. and i.p., respectively. On day 7, cohorts of mice were injected i.p. with 1 × 10^7 luciferase-positive human “double-hit” B cell lymphoma cells (36, 37), derived from unrelated donors. Lymphoma cell growth was monitored over time using an IVIS Spectrum bioluminescent imaging system, as before (36). Mice with palpable tumors were sacrificed and Kaplan-Meier survival curves plotted.

Transcriptome analysis of treated monocytes

To assess LILRB3-mediated transcriptional changes on monocytes, human PBMCs were isolated from freshly prepared PBMCs taken from healthy donors using an EasySep Human Monocyte Enrichment Kit (negative selection cell; STEMCELL Technologies). Cells were incubated in CTL medium (Cellular Technology Limited) supplemented with 100 U/mL penicillin-streptomycin, 2 mM glutamine, and HEPES buffer and treated with 10 μg/mL of an isotype control or an agonistic LILRB3 mAb (clone A1; hIgG1). Eighteen hours later, cells were lysed in RLT lysis buffer (QIAGEN) containing β-mercaptoethanol, and total RNA was extracted using the RNeasy Micro Kit (QIAGEN). Total RNA was assessed for quality and quantified using a total RNA 6000 Nano LabChip on a 2100 Bioanalyzer (Agilent Inc.), and cDNA libraries were prepared and sequenced according to the Illumina TruSeq RNA Sample Preparation Guide for SMARTer Universal Low Input RNA Kit (Clontech) and a HiSeq 2000 system (Illumina). RNA-Seq outputs were aligned to hg19 using Bowtie2 v2.2.3 (63). The number of mapped reads was quantified by RSEM v1.2.15 (64). Differential expression analysis between paired samples before and after treatment was performed using edgeR (65) with \( P < 0.05 \) and >2 fold change cutoffs. Differentially expressed genes were annotated using the online functional enrichment analysis tool Database for Annotation, Visualization and Integrated Discovery (http://david.ncifcrf.gov/) (66). GSEA was performed using Broad Institute Software (67), with the gene list preranked according to log fold change values from the edgeR output. For comparison of gene set expression, M1 and M2 macrophage gene sets (50) were obtained from the Molecular Signature Database (http://software.broadinstitute.org/gsea/msigdb/). Heatmaps were visualized with MeV (68). Raw sequences have been deposited in the National Center for Biotechnology Information's Gene Expression Omnibus with accession ID GSE151675.

Quantification of monocyte length

Human PBMCs were isolated as indicated above and then cultured for approximately 18 hours in 6-well plates in the presence of either isotype control or LILRB3 mAb (clone A1). Images were captured on an Olympus CKX41 inverted microscope, running under Olympus cellSens Standard software (version 2.1), and analyzed using ImageJ software (NIH). Length (μm) of monocytes was measured using the fragmented line tool, with the criterion of a maximum of 5 fragmented lines and exclusion of dead cells and cells found on the edges of the images. A total of 200–500 individual cell lengths were quantified from 3 independent donors.

qPCR of treated monocytes

Probe-based qPCR was used to amplify cDNA in 20 μL reactions performed in triplicate for each sample condition in a PCR plate (Bio-Rad), as per the manufacturer’s protocol. The 96-well plate was run on a C1000 Thermal Cycler CFX96 Real-Time PCR System machine (Bio-Rad). CFX manager software (Bio-Rad) was used for data acquisition and analysis of gene expression initially recorded as cycle threshold values (Ct). The Ct values were normalized to housekeeping gene GAPDH and standardized to gene expression levels in isotype control–treated samples.

Statistics

One-way ANOVA was performed for both the human leukocyte immunophenotyping and T cell proliferation data; straight bars indicate median values. On bar graphs, where at least 3 experiments were
performed, error bars represent standard deviation. Kaplan-Meier plots were analyzed by log-rank test. One-way ANOVA with Bonferroni’s multiple-comparisons test were performed for qPCR data analysis. Statistical analysis was performed using GraphPad Prism (v6-8). \( P < 0.05 \) was considered significant.

Study approval
All research with human samples and mice was performed in compliance with institutional guidelines, the Declaration of Helsinki, and the US Department of Health and Human Services Guide for the Care and Use of Laboratory Animals (National Academies Press, 2011). The Committee on Animal Care at MIT reviewed and approved the studies described here. All human samples (adult peripheral blood and fetal liver) were collected anonymously with informed consent by a third party and purchased for research. For human peripheral blood, ethical approval for the use of clinical samples was obtained by the Southampton University Hospitals NHS Trust, from the Southampton and South West Hampshire Research Ethics Committee following provision of informed consent.

Author contributions
AR and MSC were grant holders, initiated the research proposals, supervised the project, and wrote the manuscript. MY, TS, UM, UCT, BH, AL, and MM generated human LILRB3 mAbs and performed the initial screening. MY characterized the mAbs and performed the in vitro functional assays. HTCC supported the molecular biology and CP and JSM supported the in vitro assays. JT provided reagents and edited the manuscript. BF provided expert advice on the mAb generation and edited the manuscript. JC provided expert advice on the in vivo assays and edited the manuscript. AR performed the in vivo experiments in humanized mice. DCJ designed DNA constructs used to generate antibodies, performed specificity assays against LILR transfectants, and edited the manuscript. CIM performed SPR assays. GH and SMT analyzed the RNA-Seq data. IT and MJG provided expert advice on the epitope mapping and functional assays, respectively, and edited the manuscript.

Acknowledgments
We would like to thank the Antibody and Vaccine Group antibody production team, Tim Elliott (University of Southampton) and Jean-Michel Sallenave (Université Paris Diderot) for review of the manuscript, Vicentiu Pitic for advice on ImageJ analysis of human monocytes, and Hayden Fisher for modeling the LILRB3 ectodomain used in the graphical abstract. We would like to thank the Koch Institute Flow Cytometry (Glenn Paradis), Bioinformatics and Computing (Stuart Levin), and Animal Imaging and Pre-clinical Testing cores (Scott Malstrom) for their technical assistance.

This work was supported by an iCASE studentship awarded to AR, BF, and MSC to support MY from the Biotechnology and Biological Sciences Research Council and BioInvent International AB, Sweden. AR was a recipient of a Blood Cancer UK Visiting Fellowship (number 14043). Work in the JT lab was supported by European Research Council under the European Union’s Horizon 2020 research and innovation program (grant agreement 695551).

Address correspondence to: Ali Roghanian and Mark S. Cragg, Centre for Cancer Immunology, University of Southampton, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, United Kingdom. Phone: 44.2381.20.5628; Email: A.Roghanian@soton.ac.uk or aroghani@mit.edu (AR). Phone: 44.2381.20.8452; Email: msc@soton.ac.uk (MSC).

DCJ’s present address is: AstraZeneca, Granta Park, Cambridge, United Kingdom.

1. Borges L, Hsu ML, Fanger N, Kubin M, Cosman D. A family of human lymphoid and myeloid Ig-like receptors, some of which bind to MHC class I molecules. *J Immunol*. 1997;159(11):5192–5196.
2. Colonna M, et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. *J Exp Med*. 1997;186(11):1809–1818.
3. van der Touw W, Chen HM, Pan PY, Chen SH. LILRB receptor-mediated regulation of myeloid cell maturation and function. *Cancer Immunol Immunother*. 2017;66(8):1079–1087.
4. Hudson LE, Allen RL. Leukocyte Ig-like receptors - a model for MHC class I disease associations. *Front Immunol*. 2016;7:281.
5. Burshtyn DN, Marcoc C. The expanding spectrum of ligands for leukocyte Ig-like receptors. *J Immunol*. 2016;196(3):947–955.
6. Borges L, Hsu ML, Fanger N, Kubin M, Cosman D. A family of human lymphoid and myeloid Ig-like receptors, some of
which bind to MHC class I molecules. *J Immunol.* 1997;159(11):5192–5196.

7. Nakajima H, Samaridis J, Angman L, Colonna M. Human myeloid cells express an activating ILT receptor (ILT1) that associates with Fc receptor gamma-chain. *J Immunol.* 1999;162(1):5–8.

8. Chang CC, Silvia EA, Ho EK, Vlad G, Suciu-Foca N, Vasilescu ER. Polymorphism and linkage disequilibrium of immunoglobulin-like transcript 3 gene. *Hum Immunol.* 2008;69(4–5):284–290.

9. Lopez-Alvarez MR, Jones DC, Jang W, Traherne JA, Trowsdale J. Copy number and nucleotide variation of the ILIR family of myelomonocytic cell activating and inhibitory receptors. *Immunogenetics.* 2014;66(2):73–83.

10. Hirayasu K, Arase H. Functional and genetic diversity of leukocyte immunoglobulin-like receptor and implication for disease associations. *J Hum Genet.* 2015;60(11):703–708.

11. Velten FW, Duperrier K, Bohlender J, Methamor P, Goerdts S. A gene signature of inhibitory MHC receptors identifies a BDCA3(+) subset of IL-10-induced dendritic cells with reduced allostimulatory capacity in vitro. *Eur J Immunol.* 2004;34(10):2800–2811.

12. Chang CC, et al. Tolerance of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. *Nat Immunol.* 2002;3(3):237–243.

13. Beyer M, et al. High-resolution transcriptome of human macrophages. *PLoS One.* 2012;7(9):e45666.

14. Manavalan JS, et al. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. *Transpl Immunol.* 2003;11(3–4):245–258.

15. Bancheireau J, et al. Immunoglobulin-like transcript receptors on human dermal CD14+ dendritic cells act as a CD8-antagonist to control cytotoxic T cell priming. *Proc Natl Acad Sci U S A.* 2012;109(46):18885–18890.

16. Fanger NA, Cosman D, Peterson L, Braddy SC, Maliszewski CR, Borges L. The MHC class I binding proteins LIR-1 and LIR-2 inhibit Fc receptor-mediated signaling in monocytes. *Eur J Immunol.* 1998;28(11):3423–3434.

17. Barkai AA, et al., Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. *Nat Immunol.* 2018;19(1):76–84.

18. Young NT, Walter ECP, Patel R, Roghanian A, Austyn JM, Trowsdale J. The inhibitory receptor LILRB1 modulates the differentiation and regulatory potential of human dendritic cells. *Blood.* 2008;111(6):3090–3096.

19. Rochat MK, et al. Maternal vitamin D intake during pregnancy increases gene expression of ILT3 and ILT4 in cord blood. *Clin Exp Allergy.* 2010;40(5):786–794.

20. Brenk M, et al. Tryptophan deprivation induces inhibitory receptors ILT3 and ILT4 on dendritic cells favoring the induction of human CD4+CD25+Foxp3+ T regulatory cells. *J Immunol.* 2009;183(1):145–154.

21. Wagner CS, Walther-Jallow L, Buentke E, Ljunggren HG, Achour A, Chambers BJ. Human cytomegalovirus-derived protein UL18 alters the phenotype and function of monocyte-derived dendritic cells. *J Leukoc Biol.* 2008;83(1):56–63.

22. Petroff MG, Sedlmayr P, Azzola D, Hunt JS. Decidual macrophages are potentially susceptible to inhibition by class Ia and class Ib HLA molecules. *J Reprod Immunol.* 2002;56(2–3):1–17.

23. Apps R, Gardner L, Sharkey AM, Holmes N, Moffett A. A homodimeric complex of HLA-G on normal trophoblasts modulates antigen-presenting cells via LILRB1. *Eur J Immunol.* 2007;37(7):1924–1937.

24. Lombardelli L, et al. HLA-G5 induces IL-4 secretion critical for successful pregnancy through differential expression of ILT2 receptor on decidual CD4+ T cells and macrophages. *J Immunol.* 2013;191(7):3651–3662.

25. Endo S, Sakamoto Y, Kobayashi E, Nakamura A, Takai T. Regulation of cytotoxic T lymphocyte triggering by PIR-B on dendritic cells. *Proc Natl Acad Sci U S A.* 2008;105(38):14515–14520.

26. Pereira S, Zhang H, Takai T, Lowell CA. The inhibitory receptor PIR-B negatively regulates neutrophil and macrophage integrin signaling. *J Immunol.* 2004;173(9):5757–5765.

27. Wilson NS, et al. An Fcy receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. *Cancer Cell.* 2011;19(1):101–113.

28. Soderling E, et al. Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries. *Nat Biotechnol.* 2000;18(8):852–856.

29. Roghanian A, et al. Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. *Cancer Cell.* 2011;19(1):101–113.

30. Jones DC, et al. Allele-specific recognition by LILRB3 and LILRA6 of a cytokeratin 8-associated ligand on necrotic glandular epithelial cells. *Oncotarget.* 2016;7(13):15618–15631.

31. Saverino D, et al. The CD85/IL-1R-1/ILT2 inhibitory receptor is expressed by all human T lymphocytes and down-regulates their functions. *J Immunol.* 2000;165(7):3742–3755.

32. Shiroishi M, et al. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. *Proc Natl Acad Sci U S A.* 2003;100(15):8856–8861.

33. Chang CC, et al. BCL6 is required for differentiation of Ig-like transcript 3-Fc-induced CD8+ T suppressor cells. *J Immunol.* 2010;185(10):5714–5722.

34. Hussain K, et al. Upregulation of FcγRIIB on monocytes is necessary to promote the superagonist activity of TGN1412. *Blood.* 2015;125(1):102–110.

35. Dahal LN, Roghanian A, Beers SA, Cragg MS. FcγR requirements leading to successful immunotherapy. *Immunol Rev.* 2015;268(1):104–122.

36. Roghanian A, et al. Cyclophosphamide enhances cancer antibody immunotherapy in the resistant bone marrow niche by modulating macrophage FcγRI expression. *Cancer Immunol Res.* 2019;7(11):1876–1890.

37. Leskov I, et al. Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a pre-clinical model for biological therapies. *Oncogene.* 2013;32(8):1066–1072.

38. McWhorter FY, Wang T, Nguyen P, Chung T, Liu WF. Modulation of macrophage phenotype by cell shape. *Proc Natl Acad Sci U S A.* 2013;110(43):17253–17258.

39. Galvan-Pena S, O’Neill LA. Metabolic reprogramming in macrophage polarization. *Front Immunol.* 2014;5:420.

40. Khanolkar RC, Kalogeropoulos M, Lawrie A, Roghanian A, Vickers MA, Young NT. Leukocyte Ig-Like receptor B1 restrains dendritic cell function through increased expression of the NF-κB regulator ABIN1/TNIP1. *J Leukoc Biol.* 2016;100(4):737–746.
41. Zhao Y, et al. The orphan immune receptor LILRB3 modulates Fc receptor-mediated functions of neutrophils. J Immunol. 2020;204(4):954–966.
42. Sioane DE, et al. Leukocyte immunoglobulin-like receptors: novel innate receptors for human basophil activation and inhibition. Blood. 2004;104(9):2838–2839.
43. Bashirova AA, Apps R, Vince N, Mochalova Y, Yu XG, Carrington M. Diversity of the human LILRB3/A6 locus encoding a myeloid inhibitory and activating receptor pair. Immunogenetics. 2014;66(1):1–8.
44. Pescevitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006;6(5 pt 1):859–866.
45. Yu X, et al. Complex interplay between epitope specificity and isotype dictates the biological activity of anti-human CD40 antibodies. Cancer Cell. 2018;33(4):664–675.
46. Liu S, Zhang W, Horuzsako A. Human IIT2 receptor associates with murine MHC class I molecules in vivo and impairs T cell function. Eur J Immunol. 2006;36(9):2457–2471.
47. Zhang W, Liang S, Wu J, Horuzsako A. Human inhibitory receptor immunoglobulin-like transcript 2 amplifies CD11b+Gr1+ myeloid-derived suppressor cells that promote long-term survival of allografts. Transplantation. 2008;86(8):1125–1134.
48. Nakayama M, et al. Paired Ig-like receptors bind to bacteria and shape TLR-mediated cytokine production. J Immunol. 2007;178(7):4250–4259.
49. Zheng J, et al. Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development. Nature. 2012;485(7400):656–660.
50. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006;177(10):7303–7311.
51. Zais DMW, Gause WC, Osborne LC, Arts D. Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair. Immunity. 2015;42(2):216–226.
52. Hau VL, et al. Lung tumor-associated dendritic cell-derived amphiregulin increased cancer progression. J Immunol. 2011;187(4):1733–1744.
53. Vlaicu P, et al. Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator. BMC Cancer. 2013;13:197.
54. Busser B, Saney L, Brambilla E, Coll JL, Hurbin A. The multiple roles of amphiregulin in human cancer. Biochim Biophys Acta. 2011;1816(2):119–131.
55. Ogawa K, Funaba M, Chy Y, Tsujimoto M. Activin A functions as a Th2 cytokine in the promotion of the alternative activation of macrophages. J Immunol. 2006;177(10):6787–6794.
56. Picarda E, Ohaegbulam KC, Zang X. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy. Clin Cancer Res. 2016;22(14):3425–3431.
57. Suh WK, et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol. 2003;4(9):899–906.
58. Chen HM, et al. Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity. J Clin Invest. 2018;128(12):5647–5662.
59. Deng M, et al. LILRB4 signalling in leukemia cells mediates T cell suppression and tumour infiltration. Nature. 2018;562(7728):605–609.
60. Olsson N, et al. Proteomic analysis and discovery using affinity proteomics and mass spectrometry. Mol Cell Proteomics. 2011;10(10):M110.003962.
61. Roghanian A, Jones DC, Pattissapu JV, Wolfe J, Young NT, Behnam B. Filament-associated TSGA10 protein is expressed in professional antigen presenting cells and interacts with vimentin. Cell Immunol. 2010;265(2):129–126.
62. Hogan LE, Jones DC, Allen RL. Expression of the innate immune receptor LILRB5 on monocytes is associated with mycobacteria exposure. Sci Rep. 2016;6:21780.
63. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10(3):R25.
64. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323.
65. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139–140.
66. Huang DW, et al. DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res. 2007;35(Web Server issue):W169–W75.
67. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550.
68. Saeed AI, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques. 2003;34(2):374–378.